Feedback Share Discussion Threads

[ged5] 21/2/2020 12:50

Such slow going though, Bob. Still some selling going on but at least it seems to be smaller amounts now.

Another left field announcement wouldn't go amiss.

[bobd29] 21/2/2020 12:04

Good find Ged, as you say the trial results are awaited with interest. Something needed to move the share price out of its rut.

[ged5] 21/2/2020 08:44

There have been several sites recently trying to entice potential customers to purchase a report on fluoroscopy.

At just over 3000 USD I decided to give it a miss. However I did notice this paragraph:-

"Fluoroscopy and C-arms are medical imaging techniques used in variety of diagnostic and therapeutic procedures.Rising awareness of interventional surgeries is expected to fuel revenue growth of the global Fluoroscopy and C Arms market over the forecast period.However, high cost of fluoroscopy devices and C Arms is likely to restrict market growth during the forecast period. High demand for new technology like flat panel detectors and low cool down period are expected to increase the demand for fluoroscopy and C Arms in United States."

So with such demand yet high costs wouldn't it be likely that a company that can update present equipment will be getting plenty of work.

200 targeted so far by Imaging Engineering. Potential 2000 others previously mentioned. A nice little side earner maybe!

Not long to go now to hear about the results of the pilot study. I reckon mid-March.

[yump] 19/2/2020 22:36

I don’t think the director buying thing ever works out unless theres a real significant cluster.

[ducatiman] 19/2/2020 20:04

Directors still not interested at these levels? Obviously not a bargain.

[bobd29] 19/2/2020 12:33

Afternoon Lr2, welcome news if you are correct. Aside from Bleepa sales the one positive that would propel the share price would be the removal of any further fundraising need. If so expect a steady rise as the year and good news progresses, still holding to my 3p year end hope, but may revise upwards if sales volume/ JVs announced.

[ged5] 19/2/2020 12:30

At a funeral of an old colleague yesterday in windy wet Blackpool, so haven't had a proper look yet.

Well spotted, LR2. From AR's explanation of Cadran fees we were due to receive recurring sums.

I'll call out FDBK's name because it is everything and it means everything to me. Perhaps she has turned the corner!



I notice they have put a link to this page in today's tweet:-

[lr2] 18/2/2020 20:09

"In the six months to 30 November 2019, recognised revenue in the period increased 14% to £269k".

"TexRAD invoiced sales for the period totalled £128k".

So where did the other £141k come from?

Not Bleepa as yet. That would have been announced for sure.

Must therefore be Cadran as the "commercial partnership with Imaging Engineering LLC" only took place after period end.

As "a small number of initial installations have already been performed by Imaging Engineering and the first licence fees have now been received by Feedback Medical" Feedback have more licence fee income arriving in H2 and the possibility of first Bleepa revenue arriving in the near future.

Looks like a corner being turned to me.

[sonie01] 18/2/2020 18:10

LR2 I hope so but would not be surprised if it does not go up

[lr2] 18/2/2020 16:39

A corner has been turned.

[ducatiman] 18/2/2020 16:35

2.2m reported sells, 600k reported buys, up 6%. What does that tell you folks?

[yump] 18/2/2020 16:23

The good thing is, it wouldn't take much revenue to change the prospects here, although I guess that has been said a lot of times by longer term holders !

It will be interesting to see what the US licence generates - presumably they don't really know - otherwise there might be some market figures included. I never get very excited about these third party agreements, but at least they don't use up much resource.

Be good to see another trial or 2 for Bleepa running soon. Hopefully they're working through their contact list from September and any others from the past.

[peteret] 18/2/2020 16:10

I totally agree

[ducatiman] 18/2/2020 10:05

The directors will know the value of the imaging contract, how the trial is going, other imminent trials/deals. They are now free to buy. Let’s see.

[czc9] 18/2/2020 09:58

Haha if I knew that then I'd be a much more profitable investor! Instead I invest in companies like fdbk who promise much but can't deliver commercially and rely on continued dilution. ?

[dplewis1] 18/2/2020 09:11

Shouldn't you be telling us?

[czc9] 18/2/2020 08:38

I thought FDBK would need cash about March/ April and was shot down when I said it. Given the results I don't think I'm far off? What price will the next raise be at?

[ducatiman] 18/2/2020 08:07

Maybe not Ged, Directors will know!!

[ged5] 18/2/2020 08:02

As I put in 4499 good text poor figures.

I thought the text made good reading.

Figures aren't as bad as I thought. On first glance we might just have enough cash to last through to May. If we get more contracts then no problem.

Looks like we're going to have to wait for full year results to find out how lucrative the US contracts are.

[ducatiman] 18/2/2020 07:19

Nothing we don’t already know. Can’t see there being much reaction, mms might try to mug a few punters though.

[dplewis1] 18/2/2020 07:11

Those results aren't exactly exciting

[ged5] 14/2/2020 17:20

A half hour podcast with Matthew Gould, NHSX Chief Executive.

Nothing FDBK specific but outlines the challenges and opportunities for new tech companies in the NHS.

Everything to play for imo but FDBK have some work to do.



Have a good weekend.

[ducatiman] 14/2/2020 11:59

CE Mark? “Shortly”;? Lol.

[ged5] 14/2/2020 09:47

TBH I'm disappointed after reading yesterday's tweet. I'd expected some follow up tweets about how impressed attendees were with Bleepa. I can't find mention of Bleepa anywhere so far this morning. Tom Oakley isn't even on the list of published speakers (although he might have been invited after publication of the event).

The quality of that video sends out the wrong message about the company.

Not at all impressed!